 |
9/14/2022
|
|
The COVID-19 Evidence Reviews website will be discontinuing updates at the end of September 2022. The website will remain available through April 2023. Additional COVID-19 evidence resources can be found on the Resources page.
|
|
|
|
|
 |
9/07/2022
|
|
The CDC has a COVID-19 County Check tool that allows you to see the COVID-19 community levels for any U.S. county.
|
|
|
|
|
 |
8/31/2022
|
|
The FDA has authorized updated COVID-19 booster shots against the omicron subvariants. The full statement can be read at the link below.
|
|
|
|
|
 |
8/24/2022
|
|
The COVID-19 Treatment Guidelines Panel has updated the Anti-SARS-CoV-2 Monoclonal Antibodies section of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. It now includes information on the in vitro susceptibility of the circulating SARS-CoV-2 variants of concern to the available anti-SARS-CoV-2 monoclonal antibodies.
|
|
|
|
|
|
|
7/28/2022
|
|
The CDC updated has added information on the Novavax COVID-19 vaccine with an overview and safety information.
|
|
|
|
|
 |
7/14/2022
|
|
Check out our new collection for evidence syntheses on Long COVID!
|
|
|
|
|
 |
7/07/2022
|
|
The Knowledge to Policy (K2P) Center launched the K2P COVID-19 Series Initiative to provide real time evidence and bridge the gap between science, policy, and politics. K2P is a collection of evidence informed documents that aim to inform and provide insights for action to help shape the collective response needed to mitigate the COVID-19 outbreak.
|
|
|
|
|
 |
6/08/2022
|
|
Harvard T.H. Chan School of Public Health experts have been speaking to a variety of media outlets and writing articles about the pandemic to provide evidence-based context to relevant issues. You can find a selection of articles at the link below.
|
|
|
|
|
 |
6/01/2022
|
|
The COVID-19 Treatment Guidelines Panel has published a new version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, with updates on MIS-C, antithrombotic therapy, corticosteroids, and special considerations in adults and children with cancer.
|
|
|
|
|
|
|
5/19/2022
|
|
The COVID-19 Treatment Guidelines Panel has revised the Ritonavir-Boosted Nirmatrelvir (Paxlovid) section with a focus on drug-drug interactions.
|
|
|
|
|
|
|
5/05/2022
|
|
The COVID-19 Treatment Guidelines Panel has published a new version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, with updates to dosing guidance, the use of ivermectin as a treatment for COVID-19, and the use of anti-SARS-CoV-2 monoclonal antibodies.
|
|
|
|
|
 |
3/03/2022
|
|
In response to and EUA issued by the FDA, the COVID-19 Treatment Guidelines Panel has updated its recommendations on the use of bebtelovimab as an additional treatment option for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease.
|
|
|
|
|
|
|
2/24/2022
|
|
The World Health Organization maintains a global COVID-19 dashboard with information on cases, mortality, and vaccine doses.
|
|
|
|
|
|
|
2/17/2022
|
|
The CDC updated its guidance for COVID-19 vaccination following receipt of monoclonal antibodies or convalescent plasma; patients who have recently received these treatments no longer need to delay COVID-19 vaccination.
|
|
|
|
|
 |
2/11/2022
|
|
The February newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
2/02/2022
|
|
The COVID-19 Treatment Guidelines Panel (the Panel) has just published a revised version of the “Coronavirus Disease 2019 (COVID-19) Treatment Guidelines” with updated information on infection prevention, monoclonal antibodies, and special considerations for people with HIV.
|
|
|
|
|
|
|
1/26/2022
|
|
The COVID-19 Treatment Guidelines Panel have updated their statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19 to address changes to monoclonal antibody treatment due to the prevalent Omicron variant of concern.
|
|
|
|
|
|
|
1/19/2022
|
|
Every home is the U.S. is eligible to order four free at-home COVID-19 tests through USPS, beginning January 19, 2022.
|
|
|
|
|
|
|
1/12/2022
|
|
The January newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
1/06/2022
|
|
The COVID-19 Treatment Guidelines Panel have updated their recommendations on the use of tixagevimab plus cilgavimab as a pre-exposure prophylaxis in certain individuals who, if infected, are at high risk of progressing to severe COVID-19.
|
|
|
|
|
|
|
12/29/2021
|
|
The CDC issued new guidance on the recommended isolation period for people who contract COVID-19, shortening the previous recommendation of 10 days to 5 days (if asymptomatic and wearing a mask for 5 days afterwards).
|
|
|
|
|
|
|
12/23/2021
|
|
The COVID-19 Treatment Guidelines Panel have updated their recommendations, with key updates regarding therapeutic management of hospitalized adults with COVID-19, monoclonal antibodies, convalescent plasma, interferons, colchicine, and fluvoxamine.
|
|
|
|
|
 |
12/16/2021
|
|
The December newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
 |
12/08/2021
|
|
An NIH-funded study to understand the immune responses associated with vaccine-acquired protection against SARS-CoV-2 was recently published in Science. The findings of the study show that antibody levels do demonstrate some correlatation with how well a vaccine works to prevent infection.
|
|
|
|
|
|
|
12/01/2021
|
|
The CDC issued a statement on the emerging Omicron variant of COVID-19, with more information to come as it becomes availalble.
|
|
|
|
|
|
|
11/24/2021
|
|
This articles describes an innovative methodology for the development of a registry constantly updated for the scientific assessment and analysis of the health status of the population with COVID-19 in different clinical settings.
|
|
|
|
|
|
|
11/17/2021
|
|
The CDC has provided guidance for healthcare and public health providers on the use of COVID-19 vaccine boosters.
|
|
|
|
|
|
|
11/10/2021
|
|
The November newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
 |
11/03/2021
|
|
An overview of the research on long COVID by CADTH provides awareness of what is known about this condition, emerging research questions, and implications for health care systems.
|
|
|
|
|
|
|
10/27/2021
|
|
The CDC has expanded the eligibility for COVID-19 booster shots, with booster recommendations available for all three COVID-19 vaccines (Moderna, Pfizer, and Johnson & Johnson).
|
|
|
|
|
|
|
10/20/2021
|
|
The COVID-19 Treatment Guidelines Panel have updated their recommendations for the prevention of SARS-CoV-2 infection. The Panel stresses that COVID-19 vaccination remains the most effective way to prevent SARS-CoV-2 infection.
|
|
|
|
|
|
|
10/13/2021
|
|
The NSW COVID-19 Critical Intelligence Unit published a report that examines the evidence on the effectiveness of booster shots for COVID-19 vaccines.
|
|
|
|
|
|
|
10/06/2021
|
|
The COVID-19 Treatment Guidelines Panel released a statement on the EUA of bamlanivimab plus etesevimab as a post-exposure prophylaxis for selected individuals for SARS-CoV-2 infection.
|
|
|
|
|
|
|
9/29/2021
|
|
This study assesses the sensitivity of the Cochrane COVID-19 Study Register and the LOVE COVID-19 platform. The authors concluded that both platforms are sensitive enough to be “a viable screening alternative to searching every individual source”.
|
|
|
|
|
|
|
9/22/2021
|
|
This paper discusses the challenges faced when conducting LSRs in the context of the COVID-19 pandemic, and to provide methodological guidance for others doing similar work. The authors determine that a LSR is a very suitable review type for the pandemic context.
|
|
|
|
|
|
|
9/15/2021
|
|
The COVID19 Evidence Support Team (CEST) aims to produce and update the best available COVID19 evidence to facilitate decision?making in Saskatchewan, Canada. In their first year, CEST has published 135 Evidence Search Reports and 108 rapid reviews on topics related to long term care, public health and prevention, infectious diseases, personal protective equipment, vulnerable populations, and Indigenous health.
|
|
|
|
|
|
|
9/08/2021
|
|
The Health Information Research Unit (HiRU) at McMaster University provides a COVID-19 Evidence Alert service that notifies users to the current best evidence for clincial care of people with COVID-19 infection. Registration for this service is free.
|
|
|
|
|
|
|
9/01/2021
|
|
The COVID-19 Treatment Guidelines Panel has updated their guidance to include new recommendations on when to use dexamethasone in combination with intravenous (IV) sarilumab or oral tofacitinib in certain hospitalized patients with COVID-19. Click the link below to learn more.
|
|
|
|
|
|
|
8/26/2021
|
|
COVID-END and the Coronavirus Variants Rapid Response Network have published a living rapid review on the efficacy and effectiveness of available COVID-19 vaccines for variants of concern.
|
|
|
|
|
|
|
8/18/2021
|
|
The COVID-19 Treatment Guidelines Panel has published a statement on the emergency use authorization of casirivimab plus imdevimab as post-exposure prophylaxis for SARS-CoV-2 infection.
|
|
|
|
|
|
|
8/11/2021
|
|
The August newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
8/04/2021
|
|
A recently published study in the journal “Epidemiology and Infection” by Baumeister, Corrin, Abid, et al. found that many evidence syntheses on COVID-19 topics are critically low or low quality, with key domains being left out of the systematic review methodology.
|
|
|
|
|
 |
7/28/2021
|
|
The CDC publishes Science Briefs on a range of COVID-19 topics that provide a quick overview of the background and research related to a given topic of interest. These Science Briefs are updated as new evidence becomes available.
|
|
|
|
|
|
|
7/21/2021
|
|
Collabovid is a database of published and preprint studies on COVID-19 that uses natural language processing to identify the most relevant information to your query. Additional features include a geographical map of research, topic extraction, and a three-dimensional visualization of COVID-19 research.
|
|
|
|
|
|
|
7/14/2021
|
|
The COVID-19 Treatment Guidelines Panel has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, which includes updates on different treatments for COVID-19 based on the latest evidence.
|
|
|
|
|
|
|
7/08/2021
|
|
The July newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
 |
6/30/2021
|
|
The American Society of Health-System Pharmacists maintains a living evidence table for COVID-19 treatments, including antiviral agents, supporting agents, and other drugs and treatments.
|
|
|
|
|
|
|
6/23/2021
|
|
The National COVID-19 Clinical Evidence Taskforce out of Australia maintains a set of living, evidence-based guidelines related to the care of people with COVID-19.
|
|
|
|
|
|
|
6/16/2021
|
|
The COVID-19 Treatment Guidelines Panel has updated its recommendations on the use of anti-SARS-CoV-2 monoclonal antibodies in outpatients with mild to moderate COVID-19 who are at high risk of disease progression. The recommendation now includes the use of Sotrovimab following an EUA issued by the FDA.
|
|
|
|
|
|
|
6/09/2021
|
|
The June newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
6/02/2021
|
|
The VA Evidence Synthesis Program has updated its living review on the use of remdesivir in adults with COVID-19. Results from this update align with previous conclusions that remdesivir probably results in little to no difference in mortality or need for ventilation.
|
|
|
|
|
|
|
5/26/2021
|
|
The Ontario COVID-19 Science Advisory Table is a group of scientific experts and health system leaders who evaluate and report on emerging evidence relevant to the COVID-19 pandemic. This group produces Science Briefs on various topics related to COVID-19 and public health.
|
|
|
|
|
|
|
5/19/2021
|
|
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, infection control, and mental health.
|
|
|
|
|
|
|
5/12/2021
|
|
The New South Wales COVID-19 Critical Intelligence Unit provides rapid reviews that outline the available evidence on topics or questions related to the COVID-19 pandemic, with both grey and peer review literature included.
|
|
|
|
|
|
|
5/05/2021
|
|
To make decisions based on the best current evidence, patients, providers, and policy makers often look to systematic reviews and meta-analyses. This guest post by Evan Mayo Wilson, MPA, Dphil, from this past January explores the components that make a systematic review and meta-analysis a reliable source of clinical information.
|
|
|
|
|
|
|
4/28/2021
|
|
The COVID-19 Treatment Guidelines Panel has provided updated guidance on outpatient management of patients with acute COVID-19, including screening, triage, and therapeutic management. It also includes recommendations for managing patients with COVID-19 after they have been discharged from the hospital.
|
|
|
|
|
|
|
4/14/2021
|
|
The COVID-19 Treatment Guidelines Panel has updated its recommendations on the use of anti-SARS-CoV-2 monoclonal antibodies in outpatients with mild to moderate COVID-19 who are at high risk of disease progression. The FDA has approved the use of monoclonal antibodies with an Emergency Use Authorization (EUA).
|
|
|
|
|
|
|
4/07/2021
|
|
The VA ESP has published an update to its rapid review comparing the prevalence of mental health disorders among adults who have been hospitalized for COVID-19 to relevant comparison groups, assesses whether the prevalence of mental health disorders varies by patient and disease characteristics, and ascertains mental health care utilization and resource needs for adults following hospitalization for COVID-19.
|
|
|
|
|
|
|
3/30/2021
|
|
The COVID-END group from McMaster University manage a comprehensive list of COVID-19 resources, from living guidelines to single study sources.
|
|
|
|
|
|
|
3/25/2021
|
|
You can now download the entire COVID-19 Evidence Reviews dataset with the NEW “Download All Reviews” button on the homepage! The file will download as an Excel file.
|
|
|
|
|
|
|
3/17/2021
|
|
The March newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
3/10/2021
|
|
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, mental health, and infection control.
|
|
|
|
|
|
|
3/04/2021
|
|
The WHO has published a set of living guidelines on drugs to prevent COVID-19. The guidelines were created with methodological guidance from MAGIC and input from content experts, clinicians, patients, an ethicist and methodologists.
|
|
|
|
|
|
|
2/24/2021
|
|
The NIH COVID-19 Treatment Guidelines Panel have issued a statement on the EUA of bamlanivimab plus etesevimab combination for the treatment of mild to moderate COVID-19.
|
|
|
|
|
|
|
2/17/2021
|
|
A major update has been published to a living systematic review on the use of remdesivir for adults with COVID-19.
|
|
|
|
|
|
|
2/10/2021
|
|
The Society of Critical Care Management (SCCM) has updated their Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). This is the first update since June 2020 and includes nine statements related to ICU patients with severe or critical COVID-19.
|
|
|
|
|
|
|
2/04/2021
|
|
The NIH COVID-19 Treatment Guidelines Panel have updated their statement on the use of tocilizumab and other interleukin-6 inhibitors for the treatment of COVID-19 based on the results of several recent randomized controlled trials, included REMAP-CAP.
|
|
|
|
|
|
|
1/20/2021
|
|
To make decisions based on the best current evidence, patients, providers, and policy makers often look to systematic reviews and meta-analyses. This guest post by Evan Mayo Wilson, MPA, Dphil, explores the components that make a systematic review and meta-analysis a reliable source of clinical information.
|
|
|
|
|
|
|
1/15/2021
|
|
The NIH COVID-19 Treatment Guidelines Panel have been updated to include a statement on the use of ivermectin to treat COVID-19, citing incomplete evidence to support definitive conclusions about its clinical efficacy. Updated guidelines on the use of ivermection should be released in the coming weeks.
|
|
|
|
|
|
|
1/12/2021
|
|
The January newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
12/23/2020
|
|
The National Institute for Health and Care Excellence (NICE) has issued new guidance on managing the long-term effects of COVID-19, also known as “long COVID”. One in five people with COVID-19 develop this condition, and the most common symptoms are fatigue, cough, and headache.
|
|
|
|
|
|
|
12/17/2020
|
|
The NIH COVID-19 Treatment Guidelines have been updated to include current information on the clinical presentation of COVID-19, prevention and prophylaxis of SARS-CoV-2 infection, and the use of antithrombotic therapy in COVID-19 patients.
|
|
|
|
|
|
|
12/09/2020
|
|
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, mental health, and infection control.
|
|
|
|
|
|
|
12/01/2020
|
|
The November newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
11/25/2020
|
|
The NIH COVID-19 Treatment Guidelines have been updated to include a statement on the emergency use of bamlamivimab for the treatment of COVID-19.
|
|
|
|
|
|
|
11/18/2020
|
|
The University of Michigan manages the COVID-19 Best Evidence Front Door, a direct, single point of access to high quality guideline documents, meta-analyses, and literature syntheses from multiple trusted sources. The Front Door currently contains 359 evidence documents from 61 sources.
|
|
|
|
|
|
|
11/12/2020
|
|
A new Mental Health Collection collection is now available! This curated set of evidence reviews focuses on the mental health impacts of the COVID-19 pandemic on healthcare workers, patients with COVID-19, and the general public.
|
|
|
|
|
|
|
11/03/2020
|
|
The NIH COVID-19 Treatment Guidelines have been updated based on new recommendations and evidence, specifically in sections relating to remdesivir, corticosteroids and vitamin C.
|
|
|
|
|
|
|
10/23/2020
|
|
The NIH COVID-19 Treatment Guidelines have been updated to include a section titled “Influenza and COVID-19”, which provides information on managing these two illnesses concurrently.
|
|
|
|
|
|
|
10/21/2020
|
|
The Center for Evidence Based Medicine at Oxford University has been producing high quality evidence reviews and commentaries on COVID-19 topics. Many of their publications are updated regularly with new evidence.
|
|
|
|
|
|
|
10/07/2020
|
|
The October newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
9/30/2020
|
|
The Infectious Diseases Society of America provides up-to-date, evidence-based guidelines on treatment and management, infection prevention, diagnostics, and serology for COVID-19.
|
|
|
|
|
|
|
9/23/2020
|
|
Did you know that in addition to published evidence syntheses, we also catalog evidence synthesis protocols and preprints? You can find these items under Evidence Reviews > Evidence Reviews in Progress.
|
|
|
|
|
|
|
9/17/2020
|
|
The ECRI COVID-19 Resource Center is a great place to search for up-to-date clinical guidelines related to COVID-19.
|
|
|
|
|
|
|
9/11/2020
|
|
The September newsletter is here! Read about our updates on new content, features, and resources, including the new export tool. Sign up below to receive our monthly newsletters directly in your inbox!
|
|
|
|
|
|
|
9/09/2020
|
|
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, and infection control.
|
|
|
|
|
|
|
9/02/2020
|
|
The COVID-19 Treatment Guidelines Panel has released a new statement on the use of convalescent plasma to treat patients with COVID-19, citing the lack of evidence for its effectiveness and recommending against its use as the standard of care.
|
|
|
|
|
|
|
8/26/2020
|
|
Stay up to date on the latest NIH COVID-19 guidelines by subscribing to their notification email. Look for the “Sign up for updates” box on the left side of the NIH COVID-19 Treatment Guidelines website.
|
|
|
|
|
|
|
8/19/2020
|
|
The COVID-19 Evidence Reviews website has implemented some new features! Users can now download abbreviated citation information in a CSV file. We are also launching a monthly newsletter to keep our users up-to-date on key reviews, new features, and opportunities to deliver feedback. Sign up on the homepage!
|
|
|
|
|
|
|
8/12/2020
|
|
The University of Michigan manages the COVID-19 Best Evidence Front Door, a database that assembles meta-analyses, literature syntheses, and clinical guideline documents from multiple highly-reliable sources via a single search.
|
|
|
|
|
|
|
8/05/2020
|
|
The DEPRESSD Project is an international collaborative project to maintain a living systematic review on mental health topics related to COVID-19.
|
|
|
|
|
|
|
7/29/2020
|
|
The NIH released updated guidelines on July 24th regarding the use of remdesivir to treat COVID-19, based on the results of clinical trials and accounting for limited supply.
|
|
|
|
|
|
|
7/22/2020
|
|
The COVID-19 Evidence Network to Support Decision-making (COVID-END) is a comprehensive resource for rapid evidence on the COVID-19 pandemic. The purpose of COVID-END is to encourage cooperation between international evidence synthesis groups and prevent duplication of research effort.
|
|
|
|
|
|
|
7/15/2020
|
|
The VA ESP released a new report that critically appraises a study by Daniel E. Freedberg et al. on famotidine use in hospitalized COVID-19 patients. This type of study review provides additional context for the rapidly growing body of evidence related to COVID-19.
|
|
|
|
|
|
|
7/09/2020
|
|
A new living rapid review from AHRQ was recently published in Annals of Internal Medicine that provides guidance on the use of different types of masks in community and healthcare settings; the review will be updated monthly.
|
|
|
|
|
|
|
7/07/2020
|
|
The VA ESP released an updated rapid response report on corticosteroid therapy for COVID-19 infection to reflect the results from the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study.
|
|
|
|
|
|
|
7/02/2020
|
|
The NIH released new guidelines on June 25th regarding the use of dexamethasone for the treatment of patients with COVID-19, based on the results from the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study.
|
|
|
|
|
Categories